Clinical Trials Currently Enrolling at Banner – University Medical Center Tucson

Neurosurgery Clinical Trials

• A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease (NCT07106021)
• Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease (NCT06344026)
• The Ailliance Post-Market Clinical Study (NCT05856370)
• Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation  (MINUTE) Trial (NCT07260916)
• A Phase 1/2, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington’s Disease (NCT04120493)
• CraniSeal Post Approval Study (NCT06406790)

Neurology Clinical Trials

Studies regarding Stroke

• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) (NCT05702034)
• Validation of Early Prognostic Data for Recovery Outcome after Stroke for Future, Higher Yield Trials  (VERIFY) (NCT05338697)
• A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke (Revive) (NCT05953480)
• Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (NCT03907046)
• Statins use in intracerebral hemorrhage patients (NCT03936361)

Studies regarding Epilepsy

• A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (NCT05718817)
• A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (NCT05614063)
• A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) (NCT06422923)
• A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures (NCT06798896)
• A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants (NCT06937931)

Studies regarding Alzheimer’s Disease

• Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) (NCT06268886)
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) (NCT05026866)
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) (NCT04437511)
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) (NCT06653153)

For more information about these studies, contact the University of Arizona College of Medicine Tucson Department of Neurology.